Literature DB >> 17106280

Predictors of antiretroviral treatment failure in an urban HIV clinic.

Gregory K Robbins1, Brock Daniels, Hui Zheng, Henry Chueh, James B Meigs, Kenneth A Freedberg.   

Abstract

BACKGROUND: Predictors of antiretroviral treatment (ART) failure are not well characterized for heterogeneous clinic populations.
METHODS: A retrospective analysis was conducted of HIV-infected patients followed in an urban HIV clinic with an HIV RNA measurement < or =400 copies/mL on ART between January 1, 2003, and December 31, 2004. The primary endpoint was treatment failure, defined as virologic failure (> or =1 HIV RNA measurement >400 copies/mL), unsanctioned stopping of ART, or loss to follow-up. Prior ART adherence and other baseline patient characteristics, determined at the time of the first suppressed HIV RNA load on or after January 1, 2003, were extracted from the electronic health record (EHR). Predictors of failure were assessed using proportional hazards modeling.
RESULTS: Of 829 patients in the clinic, 614 had at least 1 HIV RNA measurement < or =400 copies/mL during the study period. Of these, 167 (27.2%) experienced treatment failure. Baseline characteristics associated with treatment failure in the multivariate model were: poor adherence (hazard ratio [HR] = 3.44; 95% confidence interval [CI]: 2.34 to 5.05), absolute neutrophil count <1000/mm (HR = 2.90, 95% CI: 1.26 to 6.69), not suppressed on January 1, 2003 (HR = 2.69, 95% CI: 1.78 to 4.07) or <12 months of suppression (HR = 1.64, 95% CI: 1.10 to 2.45), CD4 count <200 cells/mm (HR = 1.90, 95% CI: 1.31 to 2.76), nucleoside-only regimen (HR = 1.75, 95% CI: 1.08 to 2.82), prior virologic failure (HR = 1.70, 95% CI: 1.22 to 2.39) and > or =1 missed visit in the prior year (HR = 1.56, 95% CI: 1.13 to 2.16).
CONCLUSIONS: More than one quarter of patients in a heterogeneous clinic population had treatment failure over a 2-year period. Prior ART adherence and other EHR data readily identify patient characteristics that could trigger specific interventions to improve ART outcomes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17106280      PMCID: PMC2365745          DOI: 10.1097/01.qai.0000248351.10383.b7

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  48 in total

1.  Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort.

Authors:  D Paris; B Ledergerber; R Weber; J Jost; M Flepp; M Opravil; C Ruef; S Zimmerli
Journal:  AIDS Res Hum Retroviruses       Date:  1999-12-10       Impact factor: 2.205

2.  Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection.

Authors:  M S Sulkowski; D L Thomas; R E Chaisson; R D Moore
Journal:  JAMA       Date:  2000-01-05       Impact factor: 56.272

3.  Clinical outcome after 4 years follow-up of HIV-seropositive subjects with incomplete virologic or immunologic response to HAART.

Authors:  Emanuele Nicastri; Antonio Chiesi; Claudio Angeletti; Loredana Sarmati; Lucia Palmisano; Andrea Geraci; Massimo Andreoni; Stefano Vella
Journal:  J Med Virol       Date:  2005-06       Impact factor: 2.327

Review 4.  Adherence to medication.

Authors:  Lars Osterberg; Terrence Blaschke
Journal:  N Engl J Med       Date:  2005-08-04       Impact factor: 91.245

5.  Health information technology: shall we wait for the evidence?

Authors:  John D Halamka
Journal:  Ann Intern Med       Date:  2006-05-16       Impact factor: 25.391

Review 6.  Systematic review: impact of health information technology on quality, efficiency, and costs of medical care.

Authors:  Basit Chaudhry; Jerome Wang; Shinyi Wu; Margaret Maglione; Walter Mojica; Elizabeth Roth; Sally C Morton; Paul G Shekelle
Journal:  Ann Intern Med       Date:  2006-04-11       Impact factor: 25.391

7.  Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study.

Authors:  R Paredes; A Mocroft; O Kirk; A Lazzarin; S E Barton; J van Lunzen; T L Katzenstein; F Antunes; J D Lundgren; B Clotet
Journal:  Arch Intern Med       Date:  2000-04-24

8.  Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group.

Authors:  A Mocroft; B Ledergerber; J P Viard; S Staszewski; M Murphy; A Chiesi; A Horban; A-B E Hansen; A N Phillips; J D Lundgren
Journal:  J Infect Dis       Date:  2004-10-28       Impact factor: 5.226

9.  Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy.

Authors:  Jürgen K Rockstroh; Amanda Mocroft; Vincent Soriano; Cristina Tural; Marcello H Losso; Andrzej Horban; Ole Kirk; Andrew Phillips; Bruno Ledergerber; Jens Lundgren
Journal:  J Infect Dis       Date:  2005-08-11       Impact factor: 5.226

10.  Virological rebound after suppression on highly active antiretroviral therapy.

Authors:  Amanda Mocroft; Lidia Ruiz; Peter Reiss; Bruno Ledergerber; Christine Katlama; Adriano Lazzarin; Frank-Detlef Goebel; Andrew N Phillips; Bonaventura Clotet; Jens D Lundgren
Journal:  AIDS       Date:  2003-08-15       Impact factor: 4.177

View more
  34 in total

1.  Assessing the impact of adherence to anti-retroviral therapy on treatment failure and resistance evolution in HIV.

Authors:  Dominique Cadosch; Sebastian Bonhoeffer; Roger Kouyos
Journal:  J R Soc Interface       Date:  2012-03-14       Impact factor: 4.118

2.  HIV patients' willingness to share personal health information electronically.

Authors:  Paul A Teixeira; Peter Gordon; Eli Camhi; Suzanne Bakken
Journal:  Patient Educ Couns       Date:  2010-08-17

3.  The role of at-risk alcohol/drug use and treatment in appointment attendance and virologic suppression among HIV(+) African Americans.

Authors:  Chanelle J Howe; Stephen R Cole; Sonia Napravnik; Jay S Kaufman; Adaora A Adimora; Beth Elston; Joseph J Eron; Michael J Mugavero
Journal:  AIDS Res Hum Retroviruses       Date:  2014-01-20       Impact factor: 2.205

4.  Resistance evolution in HIV - modeling when to intervene.

Authors:  Liliana Mabel Peinado Cortes; Ryan Zurakowski
Journal:  Proc Am Control Conf       Date:  2012

5.  Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.

Authors:  E Randall Lanier; Roger G Ptak; Bernhard M Lampert; Laurie Keilholz; Tracy Hartman; Robert W Buckheit; Marie K Mankowski; Mark C Osterling; Merrick R Almond; George R Painter
Journal:  Antimicrob Agents Chemother       Date:  2010-05-03       Impact factor: 5.191

6.  African American race and HIV virological suppression: beyond disparities in clinic attendance.

Authors:  Chanelle J Howe; Sonia Napravnik; Stephen R Cole; Jay S Kaufman; Adaora A Adimora; Beth Elston; Joseph J Eron; Michael J Mugavero
Journal:  Am J Epidemiol       Date:  2014-05-08       Impact factor: 4.897

7.  Racial disparities in HIV virologic failure: do missed visits matter?

Authors:  Michael J Mugavero; Hui-Yi Lin; Jeroan J Allison; Thomas P Giordano; James H Willig; James L Raper; Nelda P Wray; Stephen R Cole; Joseph E Schumacher; Susan Davies; Michael S Saag
Journal:  J Acquir Immune Defic Syndr       Date:  2009-01-01       Impact factor: 3.731

8.  Unplanned antiretroviral treatment interruptions in southern Africa: how should we be managing these?

Authors:  Nina Veenstra; Alan Whiteside; David Lalloo; Andrew Gibbs
Journal:  Global Health       Date:  2010-03-31       Impact factor: 4.185

9.  Efficacy of a clinical decision-support system in an HIV practice: a randomized trial.

Authors:  Gregory K Robbins; William Lester; Kristin L Johnson; Yuchiao Chang; Gregory Estey; Dominic Surrao; Kimon Zachary; Sara M Lammert; Henry C Chueh; James B Meigs; Kenneth A Freedberg
Journal:  Ann Intern Med       Date:  2012-12-04       Impact factor: 25.391

10.  Impact of previous virological treatment failures and adherence on the outcome of antiretroviral therapy in 2007.

Authors:  Marie Ballif; Bruno Ledergerber; Manuel Battegay; Matthias Cavassini; Enos Bernasconi; Patrick Schmid; Bernard Hirschel; Hansjakob Furrer; Martin Rickenbach; Milos Opravil; Rainer Weber
Journal:  PLoS One       Date:  2009-12-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.